About
Chronic, non-healing wounds impact millions, generating overall cost projections exceeding $100 billion, including costs for infection management, among which surgical wounds and diabetic ulcers were the most expensive to treat.
Wound healing is a complex, dynamic cellular-based process supported by a myriad of cellular events that must be tightly coordinated to efficiently repair damaged tissue. Electric fields at wounds play a major role in wound healing and regenerative processes, with possible mechanisms involving regulation of cell migration, cell differentiation, and tissue growth.
NTMed is developing the first and only materials combining: Electrical exogenous stimulus enhancing healing processes, Best antimicrobial efficacy, and highest safety profile.
Funding history · 1 round · $800K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was NTMed founded?
- NTMed was founded in January 2020.
- What is NTMed's primary focus in product development?
- NTMed is developing materials that combine electrical exogenous stimulus for enhanced healing, antimicrobial efficacy, and a high safety profile, targeting chronic, non-healing wounds.
- What is NTMed's current funding stage and total capital raised?
- NTMed is currently in its Seed stage, having raised a total of $800,000 USD.
- When did NTMed complete its last funding round?
- NTMed completed its last funding round, a Seed round, in January 2020.
- How many employees does NTMed currently have?
- NTMed currently has 4 employees.
- Where is NTMed's headquarters located?
- NTMed's headquarters is located in the North District, Israel.
- What is NTMed's primary sector classification?
- NTMed's primary sector classification is Health Tech & Life Sciences.
- Does NTMed hold any patents?
- Yes, NTMed holds 1 patent.
- Who are the founders of NTMed?
- The founders of NTMed are Valery Diamant, Marat Lerner, and Gideon Meiry.